The CHIRON Group Acquires HSTEC

The CHIRON Group, headquartered in Tuttlingen, Germany, is continuing to follow its global growth strategy in 2022 too, and today announced its takeover of 90 percent of the Croatian company HSTEC.

The name HSTEC stands for »high speed technique«, for system expertise in development, design and manufacture of high-speed motor spindles for challenging machining. Clamping devices for machining centers and automation solutions complete the portfolio. Furthermore, HSTEC is leading the way in spindle services and repair for in-house products and spindles from other manufacturers.

With the acquisition, the CHIRON Group is expanding its capacities and strengthening three areas of expertise: Complete development, manufacturing and assembly of the key components, motor spindles and turning spindles, for the Group’s machining centers. With HSTEC fixtures for workpiece clamping, turnkey projects can be designed even better in line with customer-specific specifications. Furthermore, the CHIRON Group is expanding its services globally to include part repair, refurbishing and optimizing of all motor spindles in existing machines.

With the new name CHIRON Croatia, the CHIRON Group has a presence in eastern Europe with another of its own companies; it can support customers better in the region and will continue to develop at the Zadar site. Over 100 employees, 25 of whom alone work in engineering, increase the number of employees in the Group globally to around 1,900.

The current CEO Mladen Šarlija has been appointed Managing Director of CHIRON Croatia. The representative offices of HSTEC in Germany, the USA and China will remain, as well representation of Balluff, Bosch Rexroth, Hofmann and Mitutoyo for the Croatian market.

HSTEC will continue as a brand, joining the ranks of the CHIRON Group brands: CHIRON, STAMA, FACTORY5, CMS, GREIDENWEIS, HSTEC.

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”